Biora Therapeutics Inc
NASDAQ:BIOR
Net Margin
Biora Therapeutics Inc
Net Margin measures how much net income is generated as a percentage of revenues received. It helps investors assess if a company's management is generating enough profit from its sales and whether operating costs and overhead costs are being contained.
Net Margin Across Competitors
| Country | Company | Market Cap |
Net Margin |
||
|---|---|---|---|---|---|
| US |
|
Biora Therapeutics Inc
NASDAQ:BIOR
|
994.4k USD |
-3 536%
|
|
| US |
C
|
Cigna Group
XMUN:CGN
|
73.8B EUR |
2%
|
|
| US |
|
Cigna Corp
NYSE:CI
|
85.3B USD |
2%
|
|
| US |
|
CVS Health Corp
NYSE:CVS
|
83.8B USD |
1%
|
|
| DE |
|
Fresenius Medical Care AG
XMUN:FME
|
28B EUR |
3%
|
|
| DE |
|
Fresenius SE & Co KGaA
XETRA:FRE
|
23.7B EUR |
2%
|
|
| US |
|
Laboratory Corporation of America Holdings
NYSE:LH
|
21.7B USD |
6%
|
|
| US |
|
Quest Diagnostics Inc
NYSE:DGX
|
20B USD |
9%
|
|
| DE |
F
|
Fresenius Medical Care AG & Co KGaA
XETRA:FME
|
14B EUR |
3%
|
|
| US |
|
DaVita Inc
NYSE:DVA
|
10.9B USD |
7%
|
|
| US |
|
Hims & Hers Health Inc
NYSE:HIMS
|
9.3B USD |
9%
|
Biora Therapeutics Inc
Glance View
Progenity, Inc. engages in the provision of molecular and specialized diagnostic tests to clinicians. The company is headquartered in San Diego, California and currently employs 124 full-time employees. The company went IPO on 2020-06-19. The company delivers therapeutics in two areas: targeted delivery of therapeutics to the site of disease in the gastrointestinal tract and systemic delivery of biotherapeutics. Its research and development pipeline consists of Drug Delivery System (DDS), PGN-600, PGN-001, Oral Biotherapeutics Delivery System (OBDS), PGN-OB1 and PGN-OB2. PGN-600 is liquid formulation of tofacitinib delivered with the DDS for the treatment of ulcerative colitis. PGN-001 is an orally-delivered variant of adalimumab for the treatment of ulcerative colitis. PGN-OB1 is a combination product of a variant of adalimumab and the OBDS for the treatment of inflammatory conditions. PGN-OB2 is a combination product of a GLP-1 receptor agonist and the OBDS for the treatment of Type two diabetes. The OBDS platform is designed to enable delivery of liquid drug, reducing the need for reformulation.
See Also
Net Margin measures how much net income is generated as a percentage of revenues received. It helps investors assess if a company's management is generating enough profit from its sales and whether operating costs and overhead costs are being contained.
Based on Biora Therapeutics Inc's most recent financial statements, the company has Net Margin of -3 535.8%.
You don't have any saved screeners yet